<?xml version="1.0" encoding="UTF-8"?>
<ref id="B58-pharmaceuticals-13-00096">
 <label>58.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bellingan</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Maksimow</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Howell</surname>
    <given-names>D.C.</given-names>
   </name>
   <name>
    <surname>Stotz</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Beale</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Beatty</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Walsh</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Binning</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Davidson</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Kuper</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: An open-label study</article-title>
  <source>Lancet Respir. Med.</source>
  <year>2014</year>
  <volume>2</volume>
  <fpage>98</fpage>
  <lpage>107</lpage>
  <pub-id pub-id-type="doi">10.1016/S2213-2600(13)70259-5</pub-id>
  <pub-id pub-id-type="pmid">24503265</pub-id>
 </element-citation>
</ref>
